Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China

被引:11
|
作者
Chen, Jing-Feng [1 ]
Wu, Zhuo-Qing [2 ]
Liu, Hao-Shuang [1 ]
Yan, Su [1 ]
Wang, You-Xiang [3 ]
Xing, Miao [4 ]
Song, Xiao-Qin [1 ]
Ding, Su-Ying [1 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Hlth Management Ctr, 1 Longhu Middle Ring Rd, Zhengzhou 450052, Henan, Peoples R China
[2] Dalian Univ Technol, Inst Syst Engn, Dalian 116024, Liaoning, Peoples R China
[3] Zhengzhou Univ, Coll Publ Hlth, Zhengzhou 450001, Henan, Peoples R China
[4] Henan Univ Sci & Technol, Sch Basic Med & Forens Med, Luoyang 471003, Henan, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Metabolic dysfunction-associated fatty liver disease; High-normal alanine aminotransferase level; Cumulative effect; Cox proportional hazards regression; Cohort study; LYMPH-NODE METASTASIS; ESOPHAGEAL; MORTALITY; NOMOGRAM;
D O I
10.3748/wjg.v30.i10.1346
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND Within the normal range, elevated alanine aminotransferase (ALT) levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease (MAFLD). AIM To investigate the associations between repeated high-normal ALT measurements and the risk of new-onset MAFLD prospectively. METHODS A cohort of 3553 participants followed for four consecutive health examinations over 4 years was selected. The incidence rate, cumulative times, and equally and unequally weighted cumulative effects of excess high-normal ALT levels (ehALT) were measured. Cox proportional hazards regression was used to analyse the association between the cumulative effects of ehALT and the risk of new-onset MAFLD. RESULTS A total of 83.13% of participants with MAFLD had normal ALT levels. The incidence rate of MAFLD showed a linear increasing trend in the cumulative ehALT group. Compared with those in the low-normal ALT group, the multivariate adjusted hazard ratios of the equally and unequally weighted cumulative effects of ehALT were 1.651 [95% confidence interval (CI): 1.199-2.273] and 1.535 (95%CI: 1.119-2.106) in the third quartile and 1.616 (95%CI: 1.162-2.246) and 1.580 (95%CI: 1.155-2.162) in the fourth quartile, respectively. CONCLUSION Most participants with MAFLD had normal ALT levels. Long-term high-normal ALT levels were associated with a cumulative increased risk of new-onset MAFLD.
引用
收藏
页码:1346 / 1357
页数:13
相关论文
共 50 条
  • [21] Adverse pregnancy outcomes as a risk factor for new-onset metabolic dysfunction-associated steatotic liver disease in postpartum women: A nationwide study
    Jung, Young Mi
    Lee, Seung Mi
    Wi, Wonyoung
    Oh, Min-Jeong
    Park, Joong Shin
    Cho, Geum Joon
    Kim, Won
    JHEP REPORTS, 2024, 6 (04)
  • [22] Hepatitis C infection increases the risk of new-onset HTN and DM among patients with metabolic dysfunction-associated steatotic liver disease
    Shih, Ping-Tsung
    Shih, Chin-I
    Wu, Kuan-Ta
    Hsieh, Meng-Hsuan
    Yang, Jeng-Fu
    Chen, Yi-Yu
    Tsai, Wei-Lun
    Chen, Wen-Chi
    Liang, Po-Cheng
    Wei, Yu-Ju
    Tsai, Pei-Chien
    Hsu, Po-Yao
    Hsieh, Ming-Yen
    Lin, Yi-Hung
    Jang, Tyng-Yuan
    Wang, Chih-Wen
    Yeh, Ming-Lun
    Huang, Chung-Feng
    Huang, Jee-Fu
    Dai, Chia-Yen
    Ho, Chi-Kung
    Chuang, Wan-Long
    Yu, Ming-Lung
    JOURNAL OF HEPATOLOGY, 2024, 80 : S490 - S490
  • [23] Altitude and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in China: A Population-Based Study
    Wang, Yufei
    Meng, Qiong
    Zhang, Jin
    Guo, Bing
    Li, Nanyan
    Deng, Qian
    Hu, Julinling
    Deji, Quzong
    Guan, Han
    Danzhen, Wangjiu
    Yu, Hui
    Li, Zhifeng
    Zhou, Junmin
    HIGH ALTITUDE MEDICINE & BIOLOGY, 2024,
  • [24] Screening for metabolic dysfunction-associated fatty liver disease: Time to discard the emperor's clothes of normal liver enzymes?
    Huang, Chen-Xiao
    Zhou, Xiao-Dong
    Pan, Calvin Q.
    Zheng, Ming-Hua
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (22) : 2839 - 2842
  • [25] Sleep Factors in Relation to Metabolic Dysfunction-Associated Fatty Liver Disease in Middle-Aged and Elderly Chinese
    Yang, Jialu
    Luo, Shiyun
    Li, Rui
    Ju, Jingmeng
    Zhang, Zhuoyu
    Shen, Jichuan
    Sun, Minying
    Fan, Jiahua
    Xia, Min
    Zhu, Wei
    Liu, Yan
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (10): : 2874 - 2882
  • [26] New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice
    Canivet, Clemence M.
    Boursier, Jerome
    Loomba, Rohit
    SEMINARS IN LIVER DISEASE, 2024, 44 (01) : 35 - 42
  • [27] Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis
    Fukunaga, Shuhei
    Nakano, Dan
    Tsutsumi, Tsubasa
    Kawaguchi, Takumi
    Eslam, Mohammed
    Yoshinaga, Shinobu
    Abe, Hirohiko
    Nouno, Ryuichi
    Joh, Seiya
    Mitsuyama, Keiichi
    George, Jacob
    Torimura, Takuji
    HEPATOLOGY RESEARCH, 2022, 52 (08) : 699 - 711
  • [28] The Different Predictive Effects of Multiple Body Fat Indexes on Metabolic Dysfunction-Associated Fatty Liver Disease
    Cheng, Zhen
    Hu, Chunyu
    Zhang, Yalan
    Zhou, Jie
    Shi, Jiayang
    Sun, Li
    Chen, Zongtao
    DIABETES METABOLIC SYNDROME AND OBESITY, 2024, 17 : 3875 - 3890
  • [29] Effects of intragastric balloon placement in metabolic dysfunction-associated fatty liver disease: A systematic review and metaanalysis
    Jo?o Remí de Freitas Júnior
    Igor Braga Ribeiro
    Diogo Turiani Hourneaux de Moura
    Vitor Massaro Takamatsu Sagae
    Gabriel Mayo Vieira de Souza
    Guilherme Henrique Peixoto de Oliveira
    Sergio A Sánchez Luna
    Thiago Ferreira de Souza
    Eduardo Turiani Hourneaux de Moura
    Cláudia Pinto Marques Souza de Oliveira
    Wanderley Marques Bernardo
    Eduardo Guimar?es Hourneaux de Moura
    World Journal of Hepatology, 2021, (07) : 815 - 829
  • [30] A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease
    Hammoutene, Adel
    Laouirem, Samira
    Albuquerque, Miguel
    Colnot, Nathalie
    Brzustowski, Angelique
    Valla, Dominique
    Provost, Nicolas
    Delerive, Philippe
    Paradis, Valerie
    JHEP REPORTS, 2023, 5 (10)